News & Press

CordenPharma COVID-19 Customer Letter

Jan 1, 2022
COVID-19 > Read CEO Dr. Michael Quirmbach's Customer Letter Response to COVID-19.

CordenPharma’s Weekly Update to COVID-19 (Novel Coronavirus)

Please Read CEO & President Dr. Michael Quirmbach’s Letter to Customers

Watch our COVID-19 Video Updates and Success Stories Here

Please click here to inform us of any urgent questions or concerns regarding COVID-19

Dear Valued Customer,

Although the COVID-19 virus continues to impact our daily lives and operations at CordenPharma, the pharma industry has made great strides in providing various widely available vaccines, and I am pleased to say CordenPharma has played a significant role in that through our Lipid manufacturing. Last week, we started to see the transition back to normal with the European Commission allowing entry into the EU for travelers who have received the last recommended dose of an EU-authorized vaccine.

Therefore, beginning June 1, 2021, I have instructed all CordenPharma facility Managing Directors to assess visit requests on a case-by-case basis, taking into consideration the number of visitors requesting access, local and national government directives, business criticality of the request, geographic origin of the requesting visitors, and the vaccination status of the visiting personnel. In the absence of a completed vaccination, a negative PCR test will still need to be taken 48 hours prior to the visit.

Although we have chosen to relax our visitation rules, we will obviously monitor the situation closely, especially with the emergence of COVID-19 variants around the world. Please be aware that changes to a visit access decision may occur on short notice if deemed necessary.

Thanks to the consistent efforts and hard work of all CordenPharma employees at the site level, we have fortunately experienced minimal disruptions to our regular operations. We intend to continue this vigilance and success in the remainder of 2022.

Rest assured that all CordenPharma employees, from the Executive Leadership Team and Facility Managing Directors to the Operators and Marketing & Sales Team, are aligned and committed to mitigating any impact on delivering your critical, often lifesaving, medications. We are doing everything possible on our end to support your patients through this crisis.

We appreciate your patience as we react to this global issue, and thank you for your ongoing support in returning to “business as usual” as quickly as possible. Feel free to reach out to your Key Account Managers or fill out this form with any questions or concerns.

I wish you and your families stay safe & healthy, as we continue to work together as a collective community to support business continuity and each other.

Best Regards,

Dr. Michael Quirmbach
Chief Executive Officer & President